# Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA

> **NCT05460832** · PHASE2 · COMPLETED · sponsor: **Modern Biosciences Ltd** · enrollment: 248 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** MBS2320 5 mg
- **DRUG:** MBS2320 20 mg
- **DRUG:** MBS2320 40 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05460832
- **Lead sponsor:** Modern Biosciences Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-29
- **Primary completion:** 2023-12-28
- **Final completion:** 2024-01-03
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05460832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05460832, "Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05460832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*